MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
DFTX

DFTX

Definium Therapeutics, Inc.

$43.77
-1.04
 (-2.32%)
Exchange:  NASDAQ
Market Cap:  5.81B
Shares Outstanding:  27.377M
Delayed data
Calculate DFTX Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Robert Barrow
Full Time Employees:  106
Address: 
One World Trade Center
New York
NY
10007
US
Website:  https://definiumtx.com
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/09 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue000
Gross Profit-3,162-5270
EBITDA-92,570-105,869-178,311
Operating Income-93,866-103,916-166,309
Net Income-95,732-108,679-183,793

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets124,541302,151440,100
Total Liabilities46,40760,703107,773
Total Stockholders Equity78,134241,448332,327
Total Debt14,12921,8540
Cash and Cash Equivalents99,704273,741257,837

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-64,365-79,129-131,560
Capital Expenditure000
Free Cash Flow-64,365-79,129-131,560
Net Income-95,732-108,679-183,793
Net Change in Cash-42,438174,037-15,904

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)187,780.735Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)5,530,991.871Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)1,150,098.600Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)0Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)0Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)0Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)-28,254.322Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)1,916,535.463Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)322,004.591Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)0Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)0Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)0Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)3.600Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)21.460Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)-0.320Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)6Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
0
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-13.06
?Enterprise Value
 (TTM)
: 
5.343B  ?EV/FCF
 (TTM)
: 
-32.02
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-85.23%  ?ROIC
 (TTM)
: 
-23.81%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.04
?P/B
 (TTM)
: 
5.41  ?Current Ratio
 (TTM)
: 
6.95

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about DFTX valuation

Is Mind Medicine (MindMed) Inc. (DFTX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Mind Medicine (MindMed) Inc. (DFTX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is DFTX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether DFTX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is DFTX’s P/E ratio?

You can see DFTX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for DFTX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is DFTX a good long-term investment?

Whether DFTX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

DFTX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-2.32
MARKETSnap

Trading Metrics:

Open: 44.73   Previous Close: 44.81
Day Low: 43.44   Day High: 45.04
Year Low: 12.88   Year High: 49.2
Price Avg 50: 14.26   Price Avg 200: 14.26
Volume: 700703   Average Volume: 2.65M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Definium Therapeutics Announces New Employee Inducement Grants
15-06-2026 16:01
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics' DT120 Meets Phase III Goals in GAD Study
13-08-2026 06:05
Definium Therapeutics' DT120 Meets Phase III Goals in GAD Study
This LSD-Based Drug Just Scored Again. Definium Stock Soars.
12-08-2026 09:24
This LSD-Based Drug Just Scored Again. Definium Stock Soars.
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Prepared Remarks Transcript
06-08-2026 21:14
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Prepared Remarks Transcript
Definium Therapeutics Q2 Earnings Call Highlights
06-08-2026 21:04
Definium Therapeutics Q2 Earnings Call Highlights
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
25-06-2026 16:15
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read